The EXCEL Study: Essential Phospholipids' Impact on Fatty Liver Disease

A groundbreaking study from Opella has revealed that essential phospholipids can significantly reduce liver fat in patients with Metabolic dysfunction–Associated Steatotic Liver Disease (MASLD). The EXCEL trial, utilizing Essentiale, resulted in a 2.5 times greater reduction in liver fat compared to lifestyle changes alone.

This extensive study involved MASLD patients with conditions like type 2 diabetes and obesity, showing major improvements in fatigue and glycaemic control. MASLD affects approximately 30% of adults globally, with numbers expected to rise sharply by 2040. Known for its silent symptoms, MASLD impacts quality of life through fatigue and metabolic risks.

The research underscores the importance of early intervention and non-invasive treatments. It provides hope for innovative, evidence-based solutions in managing MASLD effectively.